tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

ROIV Stock Latest News

Roivant Sciences price target raised to $16.50 from $12 at BofA
The FlyRoivant Sciences price target raised to $16.50 from $12 at BofA
9h ago
ROIV
TD Cowen initiates $23 price target for Roivant Sciences
PremiumThe Fly
TD Cowen initiates $23 price target for Roivant Sciences
9h ago
ROIV
Roivant Sciences price target raised to $20 from $18 at Jefferies
PremiumThe Fly
Roivant Sciences price target raised to $20 from $18 at Jefferies
9h ago
MRNA
ROIV
Roivant Sciences price target raised to $21 from $15 at Guggenheim
PremiumThe Fly
Roivant Sciences price target raised to $21 from $15 at Guggenheim
9h ago
ROIV
Roivant Sciences price target raised to $20 from $16 at JPMorgan
PremiumThe Fly
Roivant Sciences price target raised to $20 from $16 at JPMorgan
10h ago
ROIV
Roivant Sciences price target raised to $20 from $18 at H.C. Wainwright
PremiumThe FlyRoivant Sciences price target raised to $20 from $18 at H.C. Wainwright
11h ago
ROIV
Yaron Werber’s Buy Rating Highlights Brepocitinib’s Potential as a Leading Treatment for Dermatomyositis
Premium
Ratings
Yaron Werber’s Buy Rating Highlights Brepocitinib’s Potential as a Leading Treatment for Dermatomyositis
23h ago
ROIV
Roivant Sciences rises 11.2%
Premium
The Fly
Roivant Sciences rises 11.2%
1d ago
ROIV
General Mills reports Q1 beat, Rithm to acquire Paramount Group: Morning Buzz
PremiumThe Fly
General Mills reports Q1 beat, Rithm to acquire Paramount Group: Morning Buzz
1d ago
CG
TS
Roivant Sciences rises 12.0%
PremiumThe Fly
Roivant Sciences rises 12.0%
1d ago
ROIV
Roivant Sciences Announces Positive Phase 3 Study Results
PremiumCompany Announcements
Roivant Sciences Announces Positive Phase 3 Study Results
1d ago
8K
ROIV
Roivant, Priovant reports Phase 3 VALOR study results for brepocitinib
PremiumThe Fly
Roivant, Priovant reports Phase 3 VALOR study results for brepocitinib
1d ago
ROIV
Roivant Sciences Approves Proposals at Annual Meeting
PremiumCompany AnnouncementsRoivant Sciences Approves Proposals at Annual Meeting
7d ago
8K
ROIV
Promising Pipeline and Strategic Positioning of Roivant Sciences: A Buy Recommendation with a $16 Price Target by 2025
Premium
Ratings
Promising Pipeline and Strategic Positioning of Roivant Sciences: A Buy Recommendation with a $16 Price Target by 2025
10d ago
ROIV
Pulmovant receives orphan drug designation from Japan MHLW for mosliciguat
Premium
The Fly
Pulmovant receives orphan drug designation from Japan MHLW for mosliciguat
14d ago
ROIV
Roivant Sciences Announces Promising Study Results
PremiumCompany Announcements
Roivant Sciences Announces Promising Study Results
15d ago
8K
ROIV
Roivant Sciences shares six-month off-treatment data in GD patients
PremiumThe Fly
Roivant Sciences shares six-month off-treatment data in GD patients
15d ago
ROIV
Roivant Sciences initiated with a Buy at Citi
PremiumThe Fly
Roivant Sciences initiated with a Buy at Citi
16d ago
ROIV
Positive Outlook for Roivant Sciences Driven by Brepocitinib’s Phase 3 Potential and Undervalued Stock
PremiumRatings
Positive Outlook for Roivant Sciences Driven by Brepocitinib’s Phase 3 Potential and Undervalued Stock
16d ago
ROIV
3 Stocks to Buy Now, According to the Technical Analysis
PremiumMarket News3 Stocks to Buy Now, According to the Technical Analysis
28d ago
CXW
ACLX
Roivant Sciences Earnings Call: Progress Amid Challenges
Premium
Company Announcements
Roivant Sciences Earnings Call: Progress Amid Challenges
1M ago
ROIV
Promising Potential of Roivant Sciences’ Brepocitinib and Pipeline Fuels Buy Rating
Premium
Ratings
Promising Potential of Roivant Sciences’ Brepocitinib and Pipeline Fuels Buy Rating
1M ago
ROIV

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >